It is made available under a CC-BY-NC-ND 4.0 International license .

1	Increased Severity of New-onset Type 1 Diabetes in Children and Adolescents during the
2	COVID-19 Pandemic: Experience from a Tertiary Care Center in Serbia
3	Damjan Jovanovic <sup>1</sup> , Jelena Blagojevic <sup>2</sup> , Dejana Stanisavljevic <sup>1,3</sup> , Maja Jesic <sup>1,2</sup>
4	<sup>1</sup> Faculty of Medicine, University of Belgrade, Serbia
5	<sup>2</sup> Department of Pediatric Endocrinology, University Children's Hospital, Belgrade, Serbia
6	<sup>3</sup> Department of Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Serbia
7	Abstract: Background and objectives: Public health measures, parental fear of infection, and redeployment of
8	medical resources in response to the COVID-19 pandemic might have led to a decrease in pediatric healthcare access.
9	As a result, a delay in type 1 diabetes diagnosis might have occurred, leading to the worsening of its clinical
10	presentation in the pediatric population. This study aimed to examine the clinical and biochemical features of new-
11	onset DM1 in children and adolescents during the COVID-19 pandemic, comparing it to the pre-pandemic period.
12	Materials and methods: The clinical and biochemical features of diabetes observed during the COVID-19 period from
13	April 1, 2020, until December 31, 2022, were compared with the period from April 1, 2017, until December 31, 2019.
14	In the COVID-19 pandemic group, the clinical and biochemical features were compared between children with and
15	without SARS-CoV-2 infection at diagnosis or before the diagnosis of DM1. Results: During the COVID-19 pandemic,
16	observed frequencies of DKA and severe DKA at diagnosis were 47.6% and 20.7%, both significantly higher than
17	during the pre-pandemic period (an absolute increase of 15% and 11.3%, respectively). In the COVID-19 group, blood
18	pH levels were significantly lower than in the pre-pandemic group, while HbA1c levels were higher. Clinical and
19	biochemical features of diabetes in children with SARS-CoV-2 infection at or before the diagnosis were not
20	significantly different compared to children without an infection. Conclusion: We report a significant worsening of
21	the clinical presentation of new-onset type 1 diabetes and an increase in the frequency of DKA and severe DKA at
22	diagnosis during the COVID-19 pandemic. Further studies are necessary to gain quantitative insight into pediatric
23	healthcare availability in Serbia.

24 Keywords: COVID-19; pandemic; Type 1 diabetes; diabetic ketoacidosis; children and adolescents; Serbia

It is made available under a CC-BY-NC-ND 4.0 International license .

## 25 1. Introduction

COVID-19 is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-26 27 CoV-2). The first cases of SARS-CoV-2 infection were reported in December 2019 in Wuhan, China. [1] The first laboratory-confirmed case of SARS-CoV-2 infection in Serbia was reported on March 6, 2020 [2], and 28 29 the World Health Organization (WHO) declared COVID-19 a pandemic on March 11 of the same year. [1] 30 The COVID-19 pandemic has proven itself to be a great challenge for healthcare systems and societies as 31 a whole throughout the world. In the Republic of Serbia, as in many other countries, a series of public 32 health measures were introduced to curb the viral spread throughout the population. In response to a 33 rising number of patients with a moderate to severe clinical presentation of the SARS-CoV-2 infection, a substantial number of hospitals were adapted for the treatment and care of COVID-19. Additionally, 34 35 numerous healthcare professionals were redeployed from their regular units to specialized COVID-19 36 centers. While severe forms of the disease in children are uncommon, it's essential to recognize that poor 37 outcomes are still plausible within the pediatric population. [3,4] Furthermore, children often act as 38 asymptomatic carriers of the virus and may serve as a significant link in the transmission chain of the 39 disease. [5,6] For those reasons, children were also subjected to public health measures.

40 Public health measures, parental fear of infection, and redeployment of healthcare system resources may 41 have led to a decrease in pediatric healthcare availability and resulted in a delay in the diagnosis and 42 treatment of other diseases [7–9], such as type 1 diabetes. A survey of the perception and experience of healthcare professionals from pediatric centers carried out during the first year of the pandemic showed 43 44 that a significant number of respondents reported a delay in the diagnosis of diabetes and an increase in 45 DKA frequency. [10] Indeed, a number of groups reported an increase in DKA and severe DKA prevalence 46 on the initial presentation of newly diagnosed type 1 diabetes in children and adolescents during the 47 pandemic. [11–15] Healthcare system overload and a decrease in pediatric healthcare access and utilization may have led to a delay in DM 1 diagnosis and a worsening of the clinical picture and 48

It is made available under a CC-BY-NC-ND 4.0 International license .

49 biochemical parameters of the disease in the Republic of Serbia as well. To evaluate this hypothesis, we 50 collected the data on disease characteristics (blood glucose levels, HbA1c, pH, DKA frequency and 51 severity) of newly diagnosed DM 1 cases presenting to the University Children's Hospital, Belgrade, Serbia, 52 over the 33 months of the COVID-19 pandemic and compared them with the data for the 33-month period 53 that immediately preceded the pandemic. Besides the indirect effects of the pandemic on the clinical 54 picture of DM 1, there is a possibility of a direct effect of the SARS-CoV-2 infection on the biology of the 55 disease. To evaluate the mechanistic effect of infection on the severity of metabolic disorder in DM 1, we 56 compared clinical and biochemical features of the disease between children who had the SARS-CoV-2 57 infection at or before the diagnosis of DM 1 and children who didn't.

# 58 2. Materials and Methods

59 The study was designed as a single-center, retrospective observational study. The study population 60 included children and adolescents less than 18 years old presenting to the Department of Pediatric 61 Endocrinology at the University Children's Hospital (Belgrade, Serbia) with new-onset type 1 diabetes. The 62 COVID-19 pandemic group included children and adolescents admitted to our department with a new 63 diagnosis of DM 1 from April 1, 2020, to December 31, 2022, while the control group was comprised of 64 patients newly diagnosed with type 1 diabetes in the period from April 1, 2017, to December 31, 2019. 65 During the COVID-19 pandemic, every child was tested for SARS-COV-2 upon admission to the hospital 66 using a rapid antigen test (RAT), and positive results were verified using polymerase chain reaction (PCR).

DM1 was defined according to the criteria of the International Society for Pediatric and Adolescent Diabetes (ISPAD). [16] Patients admitted with previous type 1 diabetes, non-DM1, or unclear types of diabetes were excluded from the study. Data collected from paper and electronic medical charts included sex, age, residence, date of DM 1 diagnosis, as well as the clinical features of the disease (symptom duration, blood pH, blood glucose levels, and DKA/severe DKA on presentation). Diabetic ketoacidosis

It is made available under a CC-BY-NC-ND 4.0 International license .

(DKA) was defined as the presence of: (1) blood glucose > 11 mmol/l, (2) blood pH < 7.3 or bicarbonate <</p>
15 mmol/l, and (3) ketonemia or ketonuria. Severe DKA was defined as pH < 7.1. [17] In the pandemic</p>
group, data were collected on the presence of SARS-CoV-2 infection before the DM1 diagnosis (history of
a positive PCR, positive RAT in the presence of symptoms, or presence of SARS-CoV-2 IgM/IgG antibodies
at any point before the diagnosis of type 1 diabetes) or at the initial presentation of DM1 (results of RAT
upon admission to the hospital).

78 **2.1. Statistical analysis** 

Data are presented as means ± standard deviation for continuous variables with a normal distribution or as numbers (percentages) for nominal variables. For comparisons between the pandemic group and prepandemic control group, as well as between the children with and without SARS-CoV-2 infection before or at the diagnosis of DM1 in the pandemic group, t-test and ANOVA were conducted for continuous variables, and the Chi-square test for nominal variables. A two-sided P < 0.05 was considered statistically significant. The data were analyzed using the Statistical Package for the Social Sciences (SPSS) Version 21 software.

#### 86 **3. Results**

A total of 143 children and adolescents presented with a new-onset DM1 over the 33-month study period during the COVID-19 pandemic, in comparison to 135 patients presenting during the equally lasting control period preceding the pandemic. The demographic characteristics of the pandemic and control groups did not differ significantly (Table 1). The average number of new DM1 cases per month during the pandemic and control period was 4.33 and 4.09, respectively. The highest average number of cases per month was recorded in 2021 (5.33), while the lowest was observed in 2018 (3.00) (Figure S1A).

It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1. Demographic and clinical/biochemical characteristics of new onset DM1 during the COVID-
19 pandemic period (April 1, 2020 to December 31, 2022) and the pre-pandemic control group (April
1, 2017 to December 31, 2019) and the pandemic group

Characteristic		Pandemic group	Control group	P value
Number of new DM1 cases	Total	143	135	/
Age	Mean ± standard deviation	9.98 ± 4.46	9.58 ± 4.39	0.446
Sex	Male Female	66 (46.2 %) 77 (53. 8%)	75 (55.6 %) 60 (44.4 %)	0.117
Residence	City of Belgrade Other	82 (57.3 %) 61 (42.7 %)	88 (65.2 %) 47 (34.8 %)	0.18
Duration of symptoms	Inconclusive ≤ 7 days 8 – 30 days ≥ 30 days	7 54 (39.7 %) 65 (47.8 %) 17 (12.5 %)	2 28 (21.1 %) 76 (57.1 %) 29 (21.8 %)	0.002
рН	Mean ± standard deviation	7.245 ± 0.175	7.317 ± 0.139	<0.001
Blood glucose level (mmol/l)	Mean ± standard deviation	23.573 ± 9.123	22.824 ± 8.767	0.487
HbA1c (%)	Mean ± standard deviation	11.041 ± 2.052	10.613 ± 1.389	0.045
DKA (%)	Total	47.6	32.6	0.011
Severe DKA (%)	Total	20.7	9.4	0.010

93

Mean blood pH values were significantly lower in the pandemic group compared to the control group 94 95  $(7.245 \pm 0.175 \text{ during the pandemic vs. } 7.317 \pm 0.139 \text{ during the control period, } P < 0.001)$  (Figure 1B), 96 while the HbA1c levels were significantly higher  $(11.041 \pm 2.052 \text{ vs.} 10.613 \pm 1.389, P = 0.045)$  (Figure 1C). 97 Mean blood glucose values were higher in the pandemic group, albeit non-significantly. The percentage of children presenting within 7 days of the onset of symptoms was higher during the pandemic (39.7% vs. 98 99 21.1%, P = 0.002), while the percentage of children with the duration of symptoms > 30 days was lower 100 (12.5% vs. 21.8%) (Table 1). During the COVID-19 pandemic, the frequency of DKA at the initial 101 presentation of type 1 diabetes was strikingly increased as compared to the control period (47.6% during

It is made available under a CC-BY-NC-ND 4.0 International license .

- the pandemic vs. 32.6% during the control period (P = 0.011), an absolute increase of 15%). The presence
- 103 of severe DKA at the onset of DM1 was also significantly more common in the pandemic group (20.7% vs.
- 104 9.4%, P = 0.01), with an absolute increase of 11.3%. (Table 1 and Figure 1A)



Figure 2. Clinical and biochemical characteristics of new onset DM1 during the COVID-19 pandemic period (April 1, 2020 to December 31, 2022) and the pre-pandemic control group (April 1, 2017 to December 31, 2019) and the pandemic group. A. During the COVID-19 pandemic frequencies of DKA and severe DKA at diagnosis were 47.6% and 20.7%, both significantly higher than during the pre-pandemic period (an absolute increase of 15% and 11.3%, respectively). B, C. HbA1c levels were significantly higher in the pandemic group, while blood pH levels were higher.

110 pandemic group, higher blood glucose levels were noticed in younger patients (27.096 ± 7.322 in children

aged < 5 years,  $23.832 \pm 9.402$  in children aged 5–11 years, and  $21.928 \pm 9.243$  in children aged  $\ge 11$  years,

It is made available under a CC-BY-NC-ND 4.0 International license .

112	P = 0.049). Such a trend of age-related decrease in mean blood glucose level wasn't seen in the control
113	group (Table 2 and Figure S2). The duration of symptoms in the pre-pandemic period was significantly
114	shorter among children aged < 5 years in comparison to other age categories (Table 2). There were no
115	significant differences in the duration of symptoms between the age groups during the COVID-19
116	pandemic. In the control group, the frequency of DKA was the highest in children aged < 5 years. While
117	the observed difference did not reach statistical significance, it's worth noting that the p-value (0.056)
118	was borderline, and its significance would have likely been revealed in a larger sample. (Table 2)

Table 2. Age-specific distribution of clinical and biochemical characteristics in individuals newly diagnosedwith DM1 during the COVID-19 pandemic and the control period

Characteristic		Pandemic group			Control group			P value	
Age		< 5	5 – 10	≥ 11	< 5	5 – 10	≥ 11	Pandemic	Control
		years	years	years	years	years	years	group	group
Duration of	≤ 7 days	48%	45.1%	31.7%	18.2%	23.7%	19.2%	0.139	0.025
symptoms	8 – 30	52%	43.1%	50%	81.8%	55.9%	48.1%		
	days	0%	11.8%	18.3%	0%	20.3%	32.7%		
	≥ 30 days								
рН	Mean ±	7.231	7.219 ±	7.271	7.259	7.320 ±	7.334	0.263	0.130
	standard	±	0.192	±	±	0.136	±		
	deviation	0.175		0.159	0.153		0.133		
Blood	Mean ±	27.096	23.832	21.928	20.309	24.653	21.748	0.049	0.076
glucose level	standard	±	± 9.402	±	±	± 9.115	±		
(mmol/l)	deviation	7.322		9.243	9.033		7.959		
HbA1c (%)	Mean ±	10.969	10.985	11.119	10.659	10.593	10.615	0.923	0.982
	standard	±	± 1.905	±	±	± 1.400	±		
	deviation	1.739		2.308	1.003		1.531		
DKA (%)	Total	50%	52.8%	42.2%	54.5%	28.3%	28.3%	0.498	0.056
Severe DKA (%)	Total	19.2%	27.5%	15.9%	15.8%	10.2%	6.0%	0.310	0.442
(/0)									

A total of 14 children (9.8%) from the pandemic cohort tested positive for SAR-CoV-2 upon admission (N
= 6, 36.2%) or had a positive history of a laboratory-confirmed SARS-CoV-2 infection before the type 1
diabetes diagnosis (N = 8, 62.8%). All children were either asymptomatic or had mild symptoms of COVID-

It is made available under a CC-BY-NC-ND 4.0 International license .

122	19. An additional 16 patients (11.18%) had a history of COVID-19 symptoms or a close contact (household
123	member with a confirmed SARS-CoV-2 infection) during the pandemic. However, no definitive
124	confirmation of the infection was established (positive PCR, positive RAT with symptoms, or the presence
125	of SARS-CoV-2 IgM/IgG antibodies) at any point before the diagnosis of DM1. Frequencies of DKA and
126	severe DKA at the onset of DM1 were similar between children who didn't have a SARS-CoV-2 infection
127	before the diagnosis of DM1 and children who tested positive for SARS-CoV-2 upon admission or had a
128	positive history of a laboratory-confirmed SARS-CoV-2 infection before the type 1 diabetes diagnosis
129	(Table 3).

Characteristic		No SARS-CoV-2 infection	SARS-CoV-2 infection	P value
Number of new DM1 cases	Total	129 (91.2%)	14 (9.8%)	
Age	Mean ± standard deviation	9.713 ± 4.388	12.450 ± 4.514	0.396
Sex	Male Female	63 (48.8%) 66 (51.2%)	3 (21.4%) 11 (78.6%)	0.051
Residence	City of Belgrade Other	75 (58.1%) 54 (41.9 %)	7 (50%) 7 (50%)	0.559
Duration of symptoms	≤ 7 days 8 – 30 days ≥ 30 days	39.7% 47.8% 12.5%	57.1% 28.6% 14.3%	0.295
рН	Mean ± standard deviation	7.239 ± 0.179	7.296 ± 0.130	0.254
Blood glucose level (mmol/l)	Mean ± standard deviation	23.676 ± 8.814	22.629 ± 11.964	0.685
HbA1c (%)	Mean ± standard deviation	11.128 ± 1.992	10.250 ± 2.477	0.129
DKA (%)	Total	47.3	50.0	0.847
Severe DKA (%)	Total	22.2	7.1	0.187

Table 3.	Characteristics	of new	onset	DM1	in childre	n with	and	without	SARS-CoV	-2 infection	າ before	or at
diagnosi	s of diabetes											

It is made available under a CC-BY-NC-ND 4.0 International license .

## 131 4. Discussion

132 Lower mean blood pH, higher mean HbA1c levels, and an increased prevalence of DKA/severe DKA on the 133 initial presentation of new-onset DM1 in the period from April 2020 to December 2022 in comparison to 134 the control period point to the worsening of the clinical picture of newly diagnosed type 1 diabetes among 135 children and adolescents during the pandemic in Serbia. Our results correspond to findings reported by a 136 number of groups from other countries [11–14,18–20], as well as several meta-analyses. [21,22] Multiple 137 factors have likely contributed to the substantial worsening of the clinical picture and biochemical 138 parameters of new-onset type 1 diabetes. In Serbia, as in numerous other countries, a series of public 139 health measures were introduced to suppress the transmission of SARS-CoV-2 in the population and 140 flatten the epidemic curve. As children may serve as asymptomatic carriers of the virus and less commonly 141 develop severe disease, public health interventions were implemented for the pediatric population as 142 well. Recommendations to decrease contact with other individuals were issued, the lockdown was 143 imposed several times, many people had to work from home, and schools and most other public 144 institutions were closed. Healthcare system overload led to changes in the organization of healthcare 145 services. In response to a high influx of moderate and severe cases of SARS-CoV-2 infection that required 146 hospitalization, a significant portion of healthcare professionals were redeployed from their regular units 147 to centers adapted for the treatment and care of patients with COVID-19, and scheduling specialist 148 appointments became increasingly difficult. Public health measures, parental fear of infection, healthcare 149 system overload, and a decrease in pediatric healthcare availability and utilization may have led to a delay 150 in the diagnosis and treatment of newly diagnosed DM1 in children and adolescents. Earlier investigations 151 have demonstrated that DKA is a preventable complication and that its risk is increased by a delay in DM1 152 diagnosis. [23,24] Moreover, the findings of the increased prevalences of DKA and severe DKA at the onset 153 of type 1 diabetes are particularly concerning, given that diabetic ketoacidosis is a life-threatening acute 154 complication of diabetes and commonly requires admission to the PICU unit.

It is made available under a CC-BY-NC-ND 4.0 International license .

155 Recent findings from several studies give evidence of an increased incidence of pediatric DM1 during the 156 COVID-19 pandemic [21,22,25,26]. Viral infections are well recognized as potential triggers for immune-157 mediated destruction of pancreatic  $\beta$  cells in type 1 diabetes, and previous epidemiological research has 158 shown a rise in new cases of DM1 following viral epidemics [27]. SARS-CoV-2 was recently identified as a 159 risk factor for the development of islet autoimmunity in young children with an increased genetic risk of 160 DM1. [28] The number of newly diagnosed DM1 cases was similar between groups in this study. However, 161 even though the University Children's Hospital in Belgrade is a tertiary care center and admits the most 162 newly diagnosed type 1 cases in Serbia, it is not the only center to provide care for pediatric diabetes in the country. As we don't have insight into the complete number of new type 1 diabetes cases diagnosed 163 164 in the territory of Serbia during the observation period, we can't estimate DM1 incidence during the 165 pandemic. Previously, an increase in the incidence of DM1 during the pandemic was reported in a multi-166 center study in Vojvodina, which is an autonomous province of the Republic of Serbia. [29] In that study, 167 Vorgucin et al. reported that the incidence of DM1 in 2021 was the highest in a five-year period from 2017 168 to 2021. That corresponds with the finding from our study that the year 2021 had the highest average 169 number of cases per month, with the average number of cases per month decreasing to the near pre-170 pandemic level in 2022.

171 Some authors point out the possibility of a direct relationship between SARS-CoV-2 infection and a more 172 severe clinical picture and DKA at the initial presentation of DM1. (18) SARS-CoV-2 penetrates the cells 173 after binding to the cell surface receptor angiotensin-converting enzyme 2 (ACE2) and proteolytic cleavage 174 of the viral spike (S) protein by transmembrane serine protease 2 (TMPRSS2) [30]. ACE 2 and other viral 175 entry factors (TMPRSS2, neuropilin 1, transferrin receptor, and furin) are expressed on the surface of 176 multiple pancreatic cell types [31], and it was demonstrated that SARS-CoV-2 can infect and replicate in 177 β-cells of Langerhans islands [32–35], leading to β-cell transdifferentiation [34], suppression of insulin 178 secretion, and induction of apoptotic pathways [35]. However, the significance of the SARS-CoV-2

It is made available under a CC-BY-NC-ND 4.0 International license .

179 mechanistic contribution to pancreatic islet dysfunction and the severity of metabolic disturbance in DM1 180 is not yet clearly established in vivo. In this study, a significant difference in clinical and laboratory 181 parameters of disease severity in DM1 between children with and without SARS-CoV-2 infection before 182 or at DM1 onset was not seen. Therefore, we believe that the worsening of clinical and laboratory 183 indicators of disease severity in children was primarily caused by the indirect effects of the pandemic on 184 pediatric healthcare service organization and access. Nevertheless, the number of SARS-CoV-2-positive 185 children in our study was small, consistent with the epidemiology of SARS-CoV-2 infection in the pediatric 186 population. Additional studies are necessary to more precisely evaluate the direct relationship between 187 viral infection and the severity of new type 1 diabetes at diagnosis.

188 This study has several important limitations. The study is single-center and conducted on a relatively small 189 sample. A larger multi-center study would provide a better insight into the effects of the pandemic on 190 pediatric DM 1 in the territory of Serbia. On the other hand, several strengths compensate for these 191 limitations. The major strength of this study is its long observation period, which has covered almost the 192 entire course of the pandemic in Serbia. To our knowledge, no similar study so far has had an observation 193 period longer than 24 months. The study is also characterized by the systematic collection of data on the 194 presence of SARS-CoV-2 infection and provides an opportunity to investigate the direct effects of the viral 195 infection on the severity of DM1.

## 196 **5. Conclusions**

In conclusion, our research adds to the growing body of literature on the relationship between the severity of new-onset DM1 in children and the COVID-19 pandemic. An increase in DKA and severe DKA frequencies at the onset of type 1 diabetes, lower mean blood pH values, and higher mean HbA1c levels confirm that the COVID-19 pandemic was associated with an increase in clinical and laboratory parameters of severity of metabolic disorder in newly diagnosed cases of DM1 in the pediatric population

It is made available under a CC-BY-NC-ND 4.0 International license .

in Serbia. We believe that the worsening of the clinical picture of type 1 diabetes and the increase in DKA/severe DKA at onset were caused by the interaction of multiple factors, among which healthcare system overload and a decrease in pediatric healthcare access and utilization stand out as the most important. Further studies are necessary to gain quantitative insight into pediatric healthcare availability and access in the Republic of Serbia.

- 207 Author Contributions: Conceptualization, D.J. and M.J.; methodology, D.J., M.J., and D.S.; software, D.S.;
- validation, D.J., M.J., and D.S.; formal analysis, D.S. and D.J.; investigation, D.J. and J.B.; resources, M.J.;
- data curation, D.J., and J.B; writing—original draft preparation, D.J.; writing—review and editing, D.J., M.J.,
- and D.S.; visualization, D.J. and D.S.; supervision, M.J.; project administration, M.J.; funding acquisition,
- 211 M.J. All authors have read and agreed to the published version of the manuscript.
- 212 Funding: This research received no external funding

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of
 Helsinki, and approved by the Ethics Committee of the University Children's Hospital, Belgrade (protocol
 code 130-26/21, 2021).

Informed Consent Statement: Informed consent was obtained from all subjects or their parents or guardians involved in the study for admission to hospitals and the procedures performed during hospitalization. A waiver was approved for individual written informed consent to publish this paper based on non-identifiable use of previously obtained retrospectively collected data.

- 220 Data Availability Statement: Data is unavailable due to privacy and ethical restrictions
- Acknowledgments: The authors would like to acknowledge the children and families cared for by the University Children's Hospital.
- 223 **Conflicts of Interest**: The authors declare no conflict of interest.

It is made available under a CC-BY-NC-ND 4.0 International license .

22	7 [1]	WHO. World Health Organization. Timeline of WHO's response to the pandemic from 31
22	8	December 2019. [Internet]. 2023 [cited 2023 Jan 1]. Available from:
22	9	https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen. n.d.
23	0 [2]	Ministarstvo zdravlja Republike Srbije, Institut za javno zdravlje "Dr Milan Jovanović Batut." COVID-
23	1	19 [Internet]. 2023 [cited 2023 Jan 1]. Available from: https://covid19.rs/. n.d.
23	2 [3]	Cui X, Zhao Z, Zhang T, Guo W, Guo W, Zheng J, et al. A systematic review and meta-analysis of
23	3	children with coronavirus disease 2019 (COVID-19). J Med Virol 2021;93:1057–69.
23	4	https://doi.org/10.1002/jmv.26398.
23	5 [4]	Kalyanaraman M, Anderson MR. COVID-19 in Children. Pediatr Clin North Am 2022;69:547–71.
23	6	https://doi.org/10.1016/j.pcl.2022.01.013.
23	7 [5]	Han MS, Choi EH, Chang SH, Jin B-L, Lee EJ, Kim BN, et al. Clinical Characteristics and Viral RNA
23	8	Detection in Children With Coronavirus Disease 2019 in the Republic of Korea. JAMA Pediatr
23	9	2021;175:73. https://doi.org/10.1001/jamapediatrics.2020.3988.
24	0 [6]	Hippich M, Holthaus L, Assfalg R, Zapardiel-Gonzalo J, Kapfelsperger H, Heigermoser M, et al. A
24	1	Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than
24	2	Reported Cases in Children. Med 2021;2:149-163.e4. https://doi.org/10.1016/j.medj.2020.10.003.
24	3 [7]	Lazzerini M, Barbi E, Apicella A, Marchetti F, Cardinale F, Trobia G. Delayed access or provision of
24	.4	care in Italy resulting from fear of COVID-19. Lancet Child Adolesc Health 2020;4:e10–1.
24	5	https://doi.org/10.1016/S2352-4642(20)30108-5.
24	6 [8]	Dayal D, Gupta S, Raithatha D, Jayashree M. Missing during COVID-19 lockdown: Children with
24	7	onset of type 1 diabetes. Acta Paediatr Oslo Nor 1992 2020;109:2144–6.
24	.8	https://doi.org/10.1111/apa.15443.
24	9 [9]	Chanchlani N, Buchanan F, Gill PJ. Addressing the indirect effects of COVID-19 on the health of
25	0	children and young people. CMAJ Can Med Assoc J J Assoc Medicale Can 2020;192:E921–7.
25	1	https://doi.org/10.1503/cmaj.201008.
25	2 [10]	Elbarbary NS, Santos TJ, Beaufort C, Agwu JC, Calliari LE, Scaramuzza AE. COVID -19 outbreak and
25	3	pediatric diabetes: Perceptions of health care professionals worldwide. Pediatr Diabetes
25	4	2020;21:1083–92. https://doi.org/10.1111/pedi.13084.
25	5 [11]	Rabbone I, Schiaffini R, Cherubini V, Maffeis C, Scaramuzza A, Diabetes Study Group of the Italian
25	6	Society for Pediatric Endocrinology and Diabetes, et al. Has COVID-19 Delayed the Diagnosis and
25	7	Worsened the Presentation of Type 1 Diabetes in Children? Diabetes Care 2020;43:2870–2.
25	8	https://doi.org/10.2337/dc20-1321.
25	9 [12]	Kamrath C, Mönkemöller K, Biester T, Rohrer TR, Warncke K, Hammersen J, et al. Ketoacidosis in
26	0	Children and Adolescents With Newly Diagnosed Type 1 Diabetes During the COVID-19 Pandemic
26	1	in Germany. JAMA 2020;324:801. https://doi.org/10.1001/jama.2020.13445.
26	2 [13]	Goldman S, Pinhas-Hamiel O, Weinberg A, Auerbach A, German A, Haim A, et al. Alarming increase
26	3	in ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the first
26	4	wave of the COVID -19 pandemic in Israel. Pediatr Diabetes 2022;23:10–8.
26	5	https://doi.org/10.1111/pedi.13296.

It is made available under a CC-BY-NC-ND 4.0 International license .

- [14] Ho J, Rosolowsky E, Pacaud D, Huang C, Lemay J-A, Brockman N, et al. Diabetic ketoacidosis at type
   1 diabetes diagnosis in children during the COVID-19 pandemic. Pediatr Diabetes 2021;22:552–7.
   https://doi.org/10.1111/pedi.13205.
- [15] Chambers MA, Mecham C, Arreola EV, Sinha M. Increase in the Number of Pediatric New-Onset
   Diabetes and Diabetic Ketoacidosis Cases During the COVID-19 Pandemic. Endocr Pract
   2022:29:470, 95, https://doi.org/10.1016/j.oprac.2022.02.005
- 271 2022;28:479–85. https://doi.org/10.1016/j.eprac.2022.02.005.
- [16] Mayer-Davis EJ, Kahkoska AR, Jefferies C, Dabelea D, Balde N, Gong CX, et al. ISPAD Clinical
   Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in
   children and adolescents. Pediatr Diabetes 2018;19 Suppl 27:7–19.
- 275 https://doi.org/10.1111/pedi.12773.
- [17] Wolfsdorf JI, Allgrove J, Craig ME, Edge J, Glaser N, Jain V, et al. Diabetic ketoacidosis and
   hyperglycemic hyperosmolar state. Pediatr Diabetes 2014;15:154–79.
   https://doi.org/10.1111/pedi.12165.
- [18] Unsworth R, Wallace S, Oliver NS, Yeung S, Kshirsagar A, Naidu H, et al. New-Onset Type 1
   Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K. Diabetes Care
   2020;43:e170–1. https://doi.org/10.2337/dc20-1551.
- [19] Lawrence C, Seckold R, Smart C, King BR, Howley P, Feltrin R, et al. Increased paediatric
   presentations of severe diabetic ketoacidosis in an Australian tertiary centre during the COVID-19
   pandemic. Diabet Med J Br Diabet Assoc 2021;38:e14417. https://doi.org/10.1111/dme.14417.
- [20] McGlacken-Byrne SM, Drew SEV, Turner K, Peters C, Amin R. The SARS-CoV-2 pandemic is
   associated with increased severity of presentation of childhood onset type 1 diabetes mellitus: A
   multi-centre study of the first COVID-19 wave. Diabet Med J Br Diabet Assoc 2021;38:e14640.
   https://doi.org/10.1111/dme.14640.
- [21] Rahmati M, Keshvari M, Mirnasuri S, Yon DK, Lee SW, Il Shin J, et al. The global impact of COVID-19
   pandemic on the incidence of pediatric new-onset type 1 diabetes and ketoacidosis: A systematic
   review and meta-analysis. J Med Virol 2022;94:5112–27. https://doi.org/10.1002/jmv.27996.
- [22] D'Souza D, Empringham J, Pechlivanoglou P, Uleryk EM, Cohen E, Shulman R. Incidence of Diabetes
   in Children and Adolescents During the COVID-19 Pandemic: A Systematic Review and Meta Analysis. JAMA Netw Open 2023;6:e2321281.
- 295 https://doi.org/10.1001/jamanetworkopen.2023.21281.
- [23] Sundaram PCB, Day E, Kirk JMW. Delayed diagnosis in type 1 diabetes mellitus. Arch Dis Child
   2008;94:151–2. https://doi.org/10.1136/adc.2007.133405.
- [24] Bui H, To T, Stein R, Fung K, Daneman D. Is Diabetic Ketoacidosis at Disease Onset a Result of
   Missed Diagnosis? J Pediatr 2010;156:472–7. https://doi.org/10.1016/j.jpeds.2009.10.001.
- Wolf RM, Noor N, Izquierdo R, Jett D, Rewers A, Majidi S, et al. Increase in newly diagnosed type 1
   diabetes in youth during the COVID-19 pandemic in the United States: A multi-center analysis.
   Pediatr Diabetes 2022;23:433–8. https://doi.org/10.1111/pedi.13328.
- Kendall EK, Olaker VR, Kaelber DC, Xu R, Davis PB. Association of SARS-CoV-2 Infection With New Onset Type 1 Diabetes Among Pediatric Patients From 2020 to 2021. JAMA Netw Open
   2022;5:e2233014. https://doi.org/10.1001/jamanetworkopen.2022.33014.
- 306 [27] Op de Beeck A, Eizirik DL. Viral infections in type 1 diabetes mellitus why the β cells? Nat Rev
   307 Endocrinol 2016;12:263–73. https://doi.org/10.1038/nrendo.2016.30.
- Lugar M, Eugster A, Achenbach P, Von Dem Berge T, Berner R, Besser REJ, et al. SARS-CoV-2
   Infection and Development of Islet Autoimmunity in Early Childhood. JAMA 2023;330:1151.
   https://doi.org/10.1001/jama.2023.16348.
- 311 [29] Vorgučin I, Savin M, Stanković Đ, Miljković D, Ilić T, Simić D, et al. Incidence of Type 1 Diabetes
- 312 Mellitus and Characteristics of Diabetic Ketoacidosis in Children and Adolescents during the First

It is made available under a CC-BY-NC-ND 4.0 International license .

- 313 Two Years of the COVID-19 Pandemic in Vojvodina. Med Kaunas Lith 2022;58:1013.
- 314 https://doi.org/10.3390/medicina58081013.
- [30] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell
   Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell
   2020;181:271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052.
- [31] Coate KC, Cha J, Shrestha S, Wang W, Gonçalves LM, Almaça J, et al. SARS-CoV-2 Cell Entry Factors
   ACE2 and TMPRSS2 Are Expressed in the Microvasculature and Ducts of Human Pancreas but Are
   Not Enriched in β Cells. Cell Metab 2020;32:1028-1040.e4.
- 321 https://doi.org/10.1016/j.cmet.2020.11.006.
- [32] Müller JA, Groß R, Conzelmann C, Krüger J, Merle U, Steinhart J, et al. Sars-Cov-2 Infects and
   Replicates in Cells of the Human Endocrine and Exocrine Pancreas. Nat Metab 2021;3:149–65.
   https://doi.org/10.1038/s42255-021-00347-1.
- [33] Steenblock C, Richter S, Berger I, Barovic M, Schmid J, Schubert U, et al. Viral infiltration of
   pancreatic islets in patients with COVID-19. Nat Commun 2021;12:3534.
   https://doi.org/10.1038/s41467-021-23886-3.
- 328 [34] Tang X, Uhl S, Zhang T, Xue D, Li B, Vandana JJ, et al. SARS-CoV-2 infection induces beta cell
- 329 transdifferentiation. Cell Metab 2021;33:1577-1591.e7.
- 330 https://doi.org/10.1016/j.cmet.2021.05.015.
- [35] Wu C-T, Lidsky PV, Xiao Y, Lee IT, Cheng R, Nakayama T, et al. SARS-CoV-2 infects human
   pancreatic β cells and elicits β cell impairment. Cell Metab 2021;33:1565-1576.e5.
- 333 https://doi.org/10.1016/j.cmet.2021.05.013.
- 334
- 335
  336
  337
  338
  339
  340
  341
  342

It is made available under a CC-BY-NC-ND 4.0 International license .

## 343 Supplementary Materials:



It is made available under a CC-BY-NC-ND 4.0 International license .



**Figure S2.** In the pandemic group, higher blood glucose levels were noticed in younger patients (27.096  $\pm$  7.322 in children aged < 5 years, 23.832  $\pm$  9.402 in children aged 5–11 years, and 21.928  $\pm$  9.243 in children aged  $\geq$  11 years, P = 0.049). Blood glucose level differences among age categories weren't significant in the control group (p = 0.076)